

# Chapter 8


## Polyphenol–Rich Formulations and Their Multi–Target Interactions With Molecular Pathways in Cancer Cells

**Emmanuel Henry Ezenabor**

 <http://orcid.org/0009-0009-0231-7734>


*Bowen University, Nigeria*

**Aminat Abisola Afolabi**

 <http://orcid.org/0009-0003-1011-2110>


*Bowen University, Nigeria*

**Oluwafemi Adeleke Ojo**

 <http://orcid.org/0000-0001-9331-396X>

*University of Turku, Finland*

**Oluyomi Stephen Adeyemi**

 <http://orcid.org/0000-0001-9342-8505>

*Bowen University, Nigeria*

### ABSTRACT

*Cancer remains the second leading cause of death globally, with classical therapies limited by selectivity, toxicity, and resistance. This review examines polyphenol-rich preparations and their multi-target interactions in cancer cells. Polyphenols (flavonoids, phenolic acids, stilbenes, lignans) simultaneously modulate multiple targets, addressing key cancer hallmarks: sustained proliferative signaling, apoptosis*

DOI: 10.4018/979-8-3373-5876-5.ch008

*evasion, replicative immortality, and angiogenesis. Key pathways include PI3K/Akt/mTOR, MAPK, RAS, and p53. Notable compounds like curcumin, resveratrol, quercetin, and EGCG induce apoptosis, inhibit angiogenesis, arrest cell cycle, and modulate epigenetics. Despite encouraging preclinical evidence, clinical translation faces challenges from low bioavailability, rapid metabolism, and conflicting data. Strategies include stable derivatives, nano-encapsulation, personalized medicine, and combination with established drugs. Polyphenolic compounds emerge as promising multi-target anticancer agents with low toxicity. Further research on bioavailability and trials is needed.*

## **1. INTRODUCTION**

Cancer continues to pose a significant global health burden, ranking as the second leading cause of death worldwide and accounting for nearly one in six deaths annually (World Health Organization, 2025). It encompasses a wide range of diseases characterized by abnormal and uncontrolled cell division, the ability to invade surrounding tissues, and, in many cases, metastasize to distant organs. The pathophysiology of cancer is complex and involves genetic mutations, epigenetic alterations, and dysregulation of multiple cellular signaling pathways (Chillón-Pino et al., 2024). Over time, cancer cells acquire several biological capabilities collectively referred to as the hallmarks of cancer which include sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, and activation of invasion and metastasis (Hanahan & Weinberg, 2011).

Traditional cancer treatments such as surgery, chemotherapy, and radiotherapy, while effective in many cases, suffer from significant drawbacks. Chemotherapeutic agents, for instance, are often non-selective, attacking both cancerous and healthy cells, leading to toxic side effects and reduced quality of life. Moreover, tumors can develop resistance to these therapies through various mechanisms such as efflux pumps, DNA repair activation, or pathway redundancy (Farhan, 2023; Emran et al., 2022). The limited specificity and adaptability of these therapies have underscored the need for novel, multi-targeted, and less toxic therapeutic alternatives. In this context, natural products, especially polyphenols, have gained substantial attention for their potential role in cancer prevention and treatment. Polyphenols are a diverse class of bioactive compounds naturally found in plants, and are abundant in fruits (such as berries, grapes, and apples), vegetables, teas, coffee, red wine, cocoa, herbs, and spices (Cháirez-Ramírez et al., 2021). Structurally, they are characterized by the presence of multiple phenol units and can be broadly categorized into flavonoids, phenolic acids, stilbenes, and lignans. These compounds are part of the

28 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: [www.igi-global.com/chapter/polyphenol-rich-formulations-and-their-multi-target-interactions-with-molecular-pathways-in-cancer-cells/403708](http://www.igi-global.com/chapter/polyphenol-rich-formulations-and-their-multi-target-interactions-with-molecular-pathways-in-cancer-cells/403708)

## Related Content

---

### A Comprehensive Review of Ethnomedical Uses, Phytochemical Studies, and Properties of Holy Basil (*Ocimum sanctum* Linn.)

Harshnad Maru, Kanchan Sharma, Saurav Kumar Mishra and George John J. (2023). *Pharmacological Benefits of Natural Agents* (pp. 49-68).

[www.irma-international.org/chapter/a-comprehensive-review-of-ethnomedical-uses-phytochemical-studies-and-properties-of-holy-basil-ocimum-sanctum-linn/327302](http://www.irma-international.org/chapter/a-comprehensive-review-of-ethnomedical-uses-phytochemical-studies-and-properties-of-holy-basil-ocimum-sanctum-linn/327302)

### Enzyme Use and Production in Industrial Biotechnology

Subir Kumar Nandy (2018). *Research Advancements in Pharmaceutical, Nutritional, and Industrial Enzymology* (pp. 341-350).

[www.irma-international.org/chapter/enzyme-use-and-production-in-industrial-biotechnology/203822](http://www.irma-international.org/chapter/enzyme-use-and-production-in-industrial-biotechnology/203822)

### ADMET Prediction and Molecular Simulation of *Prosopis juliflora* Against Lung Cancer Protein (ATK1)

Arun Pandiyan S., V. Gokul, L. Madhumitha, Vivek Pazhamalai, Ivo Romauld S. and S. S. Meenambiga (2024). *Harnessing Medicinal Plants in Cancer Prevention and Treatment* (pp. 292-308).

[www.irma-international.org/chapter/admet-prediction-and-molecular-simulation-of-prosopis-juliflora-against-lung-cancer-protein-atk1/341965](http://www.irma-international.org/chapter/admet-prediction-and-molecular-simulation-of-prosopis-juliflora-against-lung-cancer-protein-atk1/341965)

### Molecular Docking of Biologically Active Substances to Double Helical Nucleic Acids: Problems and Solutions

Kateryna V. Miroshnychenko and Anna V. Shestopalova (2016). *Applied Case Studies and Solutions in Molecular Docking-Based Drug Design* (pp. 127-157).

[www.irma-international.org/chapter/molecular-docking-of-biologically-active-substances-to-double-helical-nucleic-acids/152418](http://www.irma-international.org/chapter/molecular-docking-of-biologically-active-substances-to-double-helical-nucleic-acids/152418)

## Anti-Cancer Activities of Natural Products

Nitai Charan Giri, Bhanja Prasad Patroand Vishal Verma (2023). *Natural Products as Cancer Therapeutics* (pp. 56-105).

[www.irma-international.org/chapter/anti-cancer-activities-of-natural-products/329155](http://www.irma-international.org/chapter/anti-cancer-activities-of-natural-products/329155)